＜5759＞ Nippon Electrolysis 966 -130
Significantly, it continued to decline for 5 days. It has been announced that notes will be added to matters relating to the assumptions of continuing companies in the financial results report for the fiscal year ending 24/3. In the disclosure on the 15th, it was stated that “it has been determined that important uncertainties relating to the assumptions of continuing enterprises are not recognized,” but as a result of discussions with the accounting auditor, it was corrected to “recognize that there is an important uncertainty relating to the assumptions of continuing enterprises because there is a possibility that it will have an important impact on cash flow” based on the high level of loan balances.
＜7157＞ Lifenet 1416 +43
Significant rebound for the first time in 4 days. The investment advisory business Effissimo Capital Management holds 20.74% of Lifenet Life Insurance shares (16.647,400 shares). It became clear in the change report based on the 5% rule that it was expanded to (19.71% last time), and it has become a buyer's cause. The reporting obligation date is the 17th, and the purpose of holding is net investment (of which 16.647,300 shares are customer asset management based on discretionary investment agreements).
＜4417＞ GLOBAL SEKYU 5110 +100
Significant backlash. The year-end dividend forecast for the fiscal year ending 25/3, which had previously been undecided, was announced at 41.71 yen (previous year-end results were 26.21 yen). The annual dividend forecast is also 41.71 yen. Based on the fact that the dividend payout ratio was 25% for the fiscal year ending 24/3, the dividend payout ratio for the fiscal year ended 25/3 was set to 30% in order to further enhance profit returns and improve shareholder value. The policy is to maintain a dividend payout ratio of 30% when business results exceed expectations and increase dividend amounts.
＜4563＞ Anges 47 +1
Significantly higher. It has been announced that the release date of the progeria remedy “Zokinvi” (rare disease drug) has been decided on the 27th. It was included in drug price standards on 4/17. Zokinvi is a treatment for Hutchinson Gilford progeria syndrome (HGPS) and progeroid laminopathy (PL) with poor processing in progeria. It was sold with approval in the US in 20/11, and has also been approved in Europe and the UK. Anges has acquired exclusive sales rights in Japan.
＜4388＞ AI 861 +150
Stop height. It has been announced that a speech synthesis solution “input streaming speech synthesis API,” which enables speech to be started at high speed in cooperation with generative AI, has been newly developed and adopted in Miibo (Shibuya-ku, Tokyo)'s conversational AI construction platform. The solution supports streaming output (a format in which generated sentences are sequentially answered for each token) of generated AI, and text tokens can be sequentially inputted to the speech synthesis API. Sales are scheduled to begin in the first half of '24.
＜9331＞ caster 1446 +226
The temporary stop is high. It has been announced that a basic agreement will be concluded with Oltz (Minato-ku, Tokyo), which researches and develops personal artificial intelligence, etc. in a joint venture with product development and service operation utilizing generative AI as the main content. The investment ratio is 100% for casters, and the date of establishment is scheduled for 9/1. By combining knowledge related to product development that assumes full remote work for casters with AI element technology possessed by Ortz, we will develop businesses that respond to labor shortages, etc.